Condition
Patients scheduled for major surgery for oncologic indication
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
Treatment Research
3 treatments under study, led by Acido Acetilsalicilico Teva Italia 100 Mg Compresse Gastroresistenti
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
50%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Phase 2 (1)
Phase 3 (1)
Trial Status
Not Yet Recruiting1
Unknown1
Clinical Trials (2)
Showing 2 of 2 trials
SYFa4b84561865741b9913234ab8de0011dPhase 3Unknown
Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoing oncologic surgery (POST-CARE trial)
SYFf9d54fa100f546ccafa953112661ea98Phase 2Not Yet Recruiting
Targeting inflammation to reduce 90-day and 1-year postoperative severe morbidity in patients with unfavorable inflammatory profile undergoing oncologic surgery (POST CARE Trial)
Showing all 2 trials
Research Network
Common Treatments
- Acido Acetilsalicilico Teva Italia 100 Mg Compresse Gastroresistenti1
- Sodio Cloruro 09 Baxtersoluzione Per Infusione1
- Toradol 30 Mgml Soluzione Iniettabile1
Active Sponsors
- Fondazione IRCCS Istituto Nazionale Dei Tumori2